AIM: To understand the expression of latent and lytic genes of Epstein-Barr virus (EBV) in EBV-associated gastric carcinoma (EBVaGC) and to explore the relationship between EBV-encoded genes and development of EBVaGC at molecular level. METHODS: One hundred and seventy-two gastric carcinoma tissues and 172 corresponding para-carcinoma tissues were tested for EBV genome by polymerase chain reaction (PCR)-Southern blotting. EBV-encoded small RNA (EBER) 1 of the PCR positive specimens was detected by in situ hybridization (ISH). Gastric carcinomas with positive EBER1 signals were classified as EBVaGCs. RT-PCR and Southern hybridization were applied to the detection of expression of nuclear antigen (EBNA) promoters (Qp, Wp and Cp), EBNA 1 and EBNA 2, latent membrane proteins (LMP) 1, 2A and 2B and lytic genes (immediate early genes BZLF1 and BRLF1, early genes BARF1 and BHRF1, late genes BcLF1 and BLLF1) in EBVaGCs. RESULTS: Eleven EBV positive samples existed in gastric carcinoma tissues (6.39%). No EBV positive sample was found in corresponding para-carcinoma tissues. The difference between EBV positivity in carcinoma tissues and corresponding para-carcinoma tissues was significant (chi(2) = 9.0909, P = 0.0026). Transcripts of Qp and EBNA1 were detected in all the 11 EBVaGCs, while both Wp and Cp were silent. EBNA2, LMP1 and LMP2B mRNA were absent in all the cases, while LMP2A mRNA was detected in 4 of the 11 cases. Of the 11 EBVaGCs, 7 exhibited BcLF1 transcripts and 2 exhibited BHRF1 transcripts. The transcripts of BZLF1 and BARF1 were detected in 5 cases, respectively. No BLLF1 and BRLF mRNA were detected. CONCLUSION: The latent pattern of EBV in gastric carcinoma corresponds to the latency I/II. Some lytic infection genes are expressed in EBVaGCs tissues. BARF1 and BHRF1 genes may play an important role in tumorigenesis of gastric carcinoma.
AIM: To understand the expression of latent and lytic genes of Epstein-Barr virus (EBV) in EBV-associated gastric carcinoma (EBVaGC) and to explore the relationship between EBV-encoded genes and development of EBVaGC at molecular level. METHODS: One hundred and seventy-two gastric carcinoma tissues and 172 corresponding para-carcinoma tissues were tested for EBV genome by polymerase chain reaction (PCR)-Southern blotting. EBV-encoded small RNA (EBER) 1 of the PCR positive specimens was detected by in situ hybridization (ISH). Gastric carcinomas with positive EBER1 signals were classified as EBVaGCs. RT-PCR and Southern hybridization were applied to the detection of expression of nuclear antigen (EBNA) promoters (Qp, Wp and Cp), EBNA 1 and EBNA 2, latent membrane proteins (LMP) 1, 2A and 2B and lytic genes (immediate early genes BZLF1 and BRLF1, early genes BARF1 and BHRF1, late genes BcLF1 and BLLF1) in EBVaGCs. RESULTS: Eleven EBV positive samples existed in gastric carcinoma tissues (6.39%). No EBV positive sample was found in corresponding para-carcinoma tissues. The difference between EBV positivity in carcinoma tissues and corresponding para-carcinoma tissues was significant (chi(2) = 9.0909, P = 0.0026). Transcripts of Qp and EBNA1 were detected in all the 11 EBVaGCs, while both Wp and Cp were silent. EBNA2, LMP1 and LMP2B mRNA were absent in all the cases, while LMP2A mRNA was detected in 4 of the 11 cases. Of the 11 EBVaGCs, 7 exhibited BcLF1 transcripts and 2 exhibited BHRF1 transcripts. The transcripts of BZLF1 and BARF1 were detected in 5 cases, respectively. No BLLF1 and BRLF mRNA were detected. CONCLUSION: The latent pattern of EBV in gastric carcinoma corresponds to the latency I/II. Some lytic infection genes are expressed in EBVaGCs tissues. BARF1 and BHRF1 genes may play an important role in tumorigenesis of gastric carcinoma.
Authors: A zur Hausen; A A Brink; M E Craanen; J M Middeldorp; C J Meijer; A J van den Brule Journal: Cancer Res Date: 2000-05-15 Impact factor: 12.701
Authors: J Levitskaya; M Coram; V Levitsky; S Imreh; P M Steigerwald-Mullen; G Klein; M G Kurilla; M G Masucci Journal: Nature Date: 1995-06-22 Impact factor: 49.962
Authors: C A Kelleher; R K Paterson; D H Dreyfus; J E Streib; J W Xu; K Takase; J F Jones; E W Gelfand Journal: Virology Date: 1995-04-20 Impact factor: 3.616
Authors: J J Oudejans; A J van den Brule; N M Jiwa; P C de Bruin; G J Ossenkoppele; P van der Valk; J M Walboomers; C J Meijer Journal: Blood Date: 1995-09-01 Impact factor: 22.113
Authors: Michael Selgrad; Peter Malfertheiner; Lucia Fini; Ajay Goel; C Richard Boland; Luigi Ricciardiello Journal: J Cell Physiol Date: 2008-08 Impact factor: 6.384
Authors: Shu Su; Zhengyun Zou; Fangjun Chen; Naiqing Ding; Juan Du; Jie Shao; Lin Li; Yao Fu; Bian Hu; Yang Yang; Huizi Sha; Fanyan Meng; Jia Wei; Xingxu Huang; Baorui Liu Journal: Oncoimmunology Date: 2016-11-22 Impact factor: 8.110
Authors: Camtu D Truong; Wei Feng; Wei Li; T Khoury; Q Li; S Alrawi; Yingyan Yu; Keping Xie; James Yao; Dongfeng Tan Journal: J Exp Clin Cancer Res Date: 2009-02-03